ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 115

CTLA4-Ig/CD86 Interaction on Cultered Human Fibrocytes and Fibroblasts from Systemic Sclerosis Patients

Maurizio Cutolo1, Paola Montagna2, Stefano Soldano1, Amelia Chiara Trombetta3, Barbara Ruaro4, Paola Contini5, Sabrina Paolino6, Carmen Pizzorni4, Elisa Alessandri4, Massimo Patanè1, Alberto Sulli4, Stefano Scabini7, Emanuela Stratta7 and Renata Brizzolara1, 1Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Polyclinic San Martino Hospital, Genova, Italy, Genoa, Italy, 2Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, IRCCS Polyclinic San Martino, University of Genoa, Genova, Italy, 3Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, IRCCS Polyclinic San Martino, University of Genoa, Genoa, Italy, 4Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, San Martino Polyclinic Hospital, Genoa, Italy, Genoa, Italy, 5Division of Clinical Immunology, Department of Internal Medicine, University of Genova, IRCCS Polyclinic San Martino, Genova, Italy, Genova, Italy, 6Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, San Martino Polyclinic Hospital, Genoa, Italy, Genova, Italy, 7Oncologic Surgery, Department of Surgery, IRCCS Polyclinic San Martino, Genova, Italy, Genoa, Italy

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Abatacept, Fibroblasts, fibrosis and systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: Systemic Sclerosis and Related Disorders – Basic Science Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: CTLA4-Ig interacts with the cell surface costimulatory molecule CD86 and can downregulate the target cell activation [1]. Circulating fibrocytes (CFs) express markers of both hematopoietic cells (CD45, MHC class II) and stromal cells (collagen I and III), together with the chemokine receptors, which regulate their migration into inflammatory lesions (CXCR4, CCR2, CCR7) [2]. CFs can migrate into systemic sclerosis (SSc)-affected tissues and can differentiate into fibroblasts/myofibroblasts [2]. Skin fibroblasts (SFs) are involved in the excessive production of extracellular matrix (ECM) proteins which characterizes fibrosis in SSc [3].

The aim of the study was to compare CD86 expression on CFs, SFs and human macrophages (M) from SSc patients and to study the effects of CTLA4-Ig/CD86 interaction on SSc cultured CFs and SFs.

Methods: Peripheral blood CFs and M together with SFs were obtained from 8 “limited” cutaneous SSc patients (treated only with vasodilators, mainly cyclic prostanoids), after patient informed consent and local Ethics Committee approval for skin biopsies.

CFs and M were characterized by fluorescence-activated cell sorter analysis (FACS), for CD45, collagen type I (COL I), CXCR4, CD14, CD86, and HLA-DRII expression. After 8 days (T8) of culture, CFs were treated for 3 hrs and SFs were treated for 24 and 48 hrs, in the absence or in the presence of CTLA4-Ig (10, 50, 100 and 500 micrograms/ml). Quantitative real-time polymerase chain reaction (qRT-PCR) for CD86 on CFs, SFs and M were performed. In addition, after CTLA4-Ig treatment, qRT-PCR for CD86, COL I, IL1beta, TGFbeta, αphaSMA, S100A4, CXCR2, CXCR4, CD11a was performed. The statistical analysis was carried out by the nonparametric Mann-Whitney U test.

Results: At gene level, SSc M highly expressed CD86 molecule. Notably, T8-cultured SSc CFs showed significantly higher CD86 gene expression, compared to SSc M (p<0.05). On the contrary, SSc SFs showed a very low CD86 gene expression, compared to both M and CFs (both p<0.01). After 3 hrs-CTLA4-Ig treatments, qRT-PCR of SSc CFs showed αlphaSMA, COL I and CD11a gene expression significantly decreased (p<0.01, p<0.05 and p<0.05 respectively), whereas S100A4 gene expression resulted significantly increased (p<0.01), compared to untreated cells (CNT). CD86 and CXCR4 gene expression resulted decreased (not significantly) only after treatment with CTLA4-Ig 500 micrograms/ml. Otherwise, SSc CFs did not show any significant variations in TGFbeta, IL1beta and CXCR2 gene expressions, compared to CNT. SSc SFs treated with CTLA4-Ig did not show any significant modulation in the gene expression levels of CD86, compared to CNT.

Conclusion: In conclusion, CD86 expression on M and CFs in SSc patients might support their earlier and intensive activation in this disease when compared to resident SFs in the same patients. Therefore, SSc CFs seem to be more responsive to CTLA4-Ig treatment than SFs, thus a new therapeutic option for abatacept in SSc treatment should be taken into consideration based on its possible anti-fibrotic effect.

References: 1. Cutolo M et al. Arthritis Res Ther 2009;11:176-85; 2. Bucala R. Mol Med 2015;2:S3-5; 3. Asano Y. J Dermatol 2017; Epub ahead of print. Review.


Disclosure: M. Cutolo, Bristol Myers Squibb, 2; P. Montagna, None; S. Soldano, None; A. C. Trombetta, None; B. Ruaro, None; P. Contini, None; S. Paolino, None; C. Pizzorni, None; E. Alessandri, None; M. Patanè, None; A. Sulli, None; S. Scabini, None; E. Stratta, None; R. Brizzolara, None.

To cite this abstract in AMA style:

Cutolo M, Montagna P, Soldano S, Trombetta AC, Ruaro B, Contini P, Paolino S, Pizzorni C, Alessandri E, Patanè M, Sulli A, Scabini S, Stratta E, Brizzolara R. CTLA4-Ig/CD86 Interaction on Cultered Human Fibrocytes and Fibroblasts from Systemic Sclerosis Patients [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/ctla4-ig-cd86-interaction-on-cultered-human-fibrocytes-and-fibroblasts-from-systemic-sclerosis-patients/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/ctla4-ig-cd86-interaction-on-cultered-human-fibrocytes-and-fibroblasts-from-systemic-sclerosis-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology